Candriam S.C.A. Tcr2 Therapeutics Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$8.44 - $18.35 $7.89 Million - $17.1 Million	-934,551 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$16.41 - $24.71 $8.87 Million - $13.3 Million	540,263 Added 137.02%	934,551 $15.3 Million
Q1 2021 Apr 29, 2021	BUY	$20.38 - $34.07 $122 - $204	6 Added 0.0%	394,288 $11.7 Million
Q4 2020 Jan 22, 2021	BUY	$19.0 - $32.63 $7.49 Million - $12.9 Million	394,282 New	394,282 $12.2 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.